ID | 66682 |
FullText URL | |
Author |
Zhou, Wenhao
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawashima, Shusuke
Department of Dermatology, Chiba University Graduate School of Medicine
Ishino, Takamasa
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawase, Katsushige
Chiba Cancer Center, Research Institute
Ueda, Youki
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamashita, Kazuo
KOTAI Biotechnologies, Inc.
Watanabe, Tomofumi
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawazu, Masahito
Chiba Cancer Center, Research Institute, Division of Cell Therapy
Dansako, Hiromichi
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Suzuki, Yutaka
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
Nishikawa, Hiroyoshi
Department of Immunology, Nagoya University Graduate School of Medicine
Inozume, Takashi
Department of Dermatology, Chiba University Graduate School of Medicine
Nagasaki, Joji
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Togashi, Yosuke
Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
researchmap
|
Abstract | Immune checkpoint inhibitors exert clinical efficacy against various types of cancer through reinvigoration of exhausted CD8+ T cells that attack cancer cells directly in the tumor microenvironment (TME). Using single-cell sequencing and mouse models, we show that CXCL13, highly expressed in tumor-infiltrating exhausted CD8+ T cells, induces CD4+ follicular helper T (TFH) cell infiltration, contributing to anti-tumor immunity. Furthermore, a part of the TFH cells in the TME exhibits cytotoxicity and directly attacks major histocompatibility complex-II-expressing tumors. TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
|
Keywords | cancer immunology
follicular helper T cell
cytotoxic CD4+ T cell
CXCL13
T cell exhaustion
stem-like progenitor exhaustion
terminally differentiated exhaustion
PD-1
LAG-3
TCF1
|
Note | Immune checkpoint inhibitors exert clinical efficacy against various types of cancer through reinvigoration of exhausted CD8+ T cells that attack cancer cells directly in the tumor microenvironment (TME). Using single-cell sequencing and mouse models, we show that CXCL13, highly expressed in tumor-infiltrating exhausted CD8+ T cells, induces CD4+ follicular helper T (TFH) cell infiltration, contributing to anti-tumor immunity. Furthermore, a part of the TFH cells in the TME exhibits cytotoxicity and directly attacks major histocompatibility complex-II-expressing tumors. TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
|
Published Date | 2024-02-27
|
Publication Title |
Cell Reports
|
Volume | volume43
|
Issue | issue2
|
Publisher | Elsevier BV
|
Start Page | 113797
|
ISSN | 2211-1247
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2024 The Author(s).
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1016/j.celrep.2024.113797
|
License | http://creativecommons.org/licenses/by/4.0/
|
Funder Name |
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Japan Science and Technology Agency
Naito Foundation
Astellas Foundation for Research on Metabolic Disorders
Wesco Foundation
Uehara Memorial Foundation
Senri Life Science Foundation
Relay for Life Japan Cancer Society Foundation
Japan Research Foundation for Clinical Pharmacology
Takeda Science Foundation
Kowa Life Science Foundation
Chugai Foundation for Innovative Drug Discovery Science
Yasuda Medical Foundation
SGH Foundation
KOTAI Biotechnologies, Inc.
|
助成番号 | 22K1945904
21H05051
20H03694
19K08744
22K20824
22K15472
23K14594
19cm0106502
21cm0106383
19ck0106521h0001
22ck0106775h0001
22gm1810002s0101
21-211033868
|